New Research on Gender-Affirming Testosterone and Fertility

Mouse model of gender-affirming testosterone treatment and fertility finds decrease in egg yield but not quality

12:00 PM

Jump to Transcript

Evidence can help inform fertility care for transgender and gender diverse people who wish to become parents. Visit Health Lab to read the full story.

Transcript

Host: 

Welcome to Health Lab, your destination for news and stories about the future of healthcare. Today: New research can help inform fertility care for transgender and gender diverse people who wish to become parents.

Although transgender and gender diverse young adults demonstrate a high interest in parenting, less than 20% of transgender and nonbinary individuals in the United States are parents.

Transgender and gender diverse people who wish to become parents face barriers including discrimination in the health care setting, access to high quality fertility care and high cost as fertility care is not typically covered by public or private insurers.

Beyond logistic barriers to receiving fertility treatment, the potential stress of halting gender-affirming hormones before treatment poses an additional challenge.

Organizations recommend doctors council patients who are beginning gender-affirming treatment about fertility preservation to avoid pausing hormones later.

However, freezing eggs or sperm is often cost prohibitive for an 18 or 19-year-old adult patient beginning gender-affirming hormones.

The current recommendation is for patients to stop taking gender-affirming hormones for up to a three month “washout period” before in vitro fertilization, commonly known as IVF, says Molly Moravek, M.D, M.P.H., MSCI, a reproductive endocrinologist at Michigan Medicine.

“It’s unfair that we are advising people to make life changing interventions by spending thousands of dollars to freeze eggs or halting testosterone for three months before IVF out of fear that testosterone treatment might affect their fertility,” said Moravek.

“We worry testosterone might affect their fertility outcome, but we don’t have any evidence for that claim.”

To remedy this, Moravek led a University of Michigan team with Ariella Shikanov, Ph.D., and Vasantha Padmanabhan, Ph.D., to investigate how gender-affirming testosterone treatment affected IVF outcomes using a mouse model.

Researchers divided genetically identical female mice into four treatment groups: a control implant, a testosterone implant, a control implant washout and a testosterone implant washout.

The first two groups underwent ovarian stimulation for egg collection with hormone implants in place while the washout groups had the hormone implant removed for two weeks before ovarian stimulation.

Eggs were then collected, fertilized and cultured in vitro for early embryonic stages.

The experiment was conducted twice with testosterone implants in place for six or 12 weeks to represent short and long-term testosterone exposure.

The researchers found that testosterone treatment decreased egg yield without affecting quality.

For the short-term testosterone treatment group with a two-week washout, IVF outcomes were fully recovered to the level of controls.

However, IVF outcomes were not fully recovered for the long-term testosterone treatment group.

“In mice, we’re seeing that you may get less eggs with testosterone treatment, but those eggs are fine and still create normal embryos that become live born offspring,” said Moravek.

The researchers plan to investigate whether there is a medication that can clear out the eggs to hasten the washout period.

Moravek also plans to study multiple generations of mice to determine whether the offspring of gender-affirming testosterone treated parents experience any reduced fertility or metabolic effects.

As evidence builds, this information can help inform conversations between doctors and patients when deciding whether to halt gender-affirming testosterone treatment before IVF.

“Some patients are comfortable halting gender-affirming testosterone. For others, it can be very distressing,” said Moravek.

For the subset of patients who would be distressed by stopping gender-affirming testosterone, ovarian reserve – or the number of eggs remaining in the ovaries – can help direct the conversation, says Moravek.

The egg loss may not be a concern for a patient with a great ovarian reserve but for a patient with a low ovarian reserve, it will be important to discuss the pros and cons of continuing gender-affirming testosterone.

“We owe it to our patients to have data to back up decisions before we tell them to do these expensive and emotionally taxing procedures,” said Moravek.

For more on this story and others like it, visit michiganmedicine.org/health-lab. Health Lab is a part of the Michigan Medicine Podcast Network and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab wherever you listen to podcasts.


More Articles About: Healthcare Transgender fertility reproductive endocrinology podcast Michigan Medicine
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast

Listen to more Health Lab podcasts - a part of the Michigan Medicine Podcast Network.

Featured News & Stories Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Can a Serious Infection Increase the Risk of Developing Dementia?
In this episode, Lauren and Matt talk with Leah Richmond-Rakerd, PhD who is an Assistant Professor in the Department of Psychology at the University of Michigan. Her research focuses on emotional and behavioral dysregulation across the life course. Here, Dr. Richmond-Rakerd will discuss her recent study on “The Associations of Hospital-Treated Infections with Subsequent Dementia: Nationwide 30-year Analysis” that was published in Nature Aging.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
The Return of Minding Memory
Welcome to Season 4 of Minding Memory, where we are welcoming a new co-host, Lauren Gerlach to the Minding Memory team. Lauren is a Geriatric Psychiatrist at the University of Michigan and a member of the CAPRA leadership team. In this episode, Lauren shares a little background on her research interests, what it’s like to be a geriatric psychiatrist, and some lessons learned about using “uncool” emoticons or emojis when texting.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
It’s back to school season for viruses too
What to know about the uptick in B19 and other respiratory illnesses expected to have a comeback in colder seasons.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
How mental health policy aimed at increasing access has impacted new moms
A recent study finds that after two major health policy shifts aimed at increasing access to care, slightly more pregnant and postpartum women with depression or anxiety received psychotherapy.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
What health care concerns matter most to older adults this election?
All types of health care costs, and financial scams, rise to the top.
Text over image of University of Michigan Health aerial campus
News Release
U-M Health ranked among nation’s best in more specialties than any other Michigan hospital by U.S. News & World Report
University of Michigan Health ranks among the nation’s best hospitals in more specialties than any other Michigan hospital, according to U.S. News and World Report’s Best Hospitals Rankings for 2024-2025.